Status:
COMPLETED
A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to evaluate how much of the study drug (LY3556050), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into ...
Eligibility Criteria
Inclusion
- Male participants who are overtly healthy as determined by medical evaluation
- Have a body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m²), inclusive
- Males who agree to use highly effective or effective methods of contraception
Exclusion
- Have known allergies to LY3556050, related compounds, or any components of the formulation of LY3556050, or history of significant atopy
- Have clinically significant abnormal BP and/or pulse rate as determined by the investigator
- Have had exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing
Key Trial Info
Start Date :
September 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 4 2023
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT06052462
Start Date
September 20 2023
End Date
November 4 2023
Last Update
January 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
LabCorp CRU, Inc.
Madison, Wisconsin, United States, 53704